ACM
CKPT

ACT Capital Management’s Checkpoint Therapeutics CKPT Stock Holding History

ACT Capital Management’s Portfolio CKPT Stock Details CKPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-20,500
Closed -$605K – 115
2021
Q2 		$605K Buy
+20,500
New +$568K 0.31% 60

Other funds holding CKPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SAG
Spotlight Asset Group Oakbrook Terrace, Illinois $143M AUM 20.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
EL
EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return

ACT Capital Management's CKPT Position: Q3 2021 in Review

ACT Capital Management sold out of Checkpoint Therapeutics (CKPT) in Q3 2021, closing a stake of 20,500 shares — an estimated $605K sold.

ACT Capital Management first reported a position in CKPT in Q2 2021 and held it in 1 quarter. The position peaked at $605K in Q2 2021. 67 funds tracked by Wall St. Rank hold CKPT as of Q3 2021.

  • ACT Capital Management reported no remaining Checkpoint Therapeutics position as of Q3 2021 after selling out during the quarter.
  • ACT Capital Management sold 20,500 Checkpoint Therapeutics shares in Q3 2021, an estimated $605K.
  • ACT Capital Management first reported a position in Checkpoint Therapeutics in Q2 2021 and held it in 1 quarter.
  • ACT Capital Management's Checkpoint Therapeutics position peaked at $605K in Q2 2021.
  • 67 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q3 2021.

Based on ACT Capital Management's 13F filing for Q3 2021, filed 16 Nov 2021.